J&J Challenged Over Schizophrenia Drug Patent

Law360, New York (October 17, 2005, 12:00 AM EDT) -- Barr Laboratories Inc. has challenged Johnson & Johnson’s patent for a schizophrenia drug, triggering a lawsuit from the health care giant over the widely prescribed antipsychotic.

J&J filed the suit in early October after Barr informed the company of its Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration. The application included a Paragraph IV certification challenging the validity of J&J’s patent, compelling Barr to inform J&J of its intentions.

The suit was filed against the New Jersey-based generic drug maker by J&J’s...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.